A Phase I, Open Label, Parallel Group, Multi-center Single Dose Trial to Evaluate the Effect of Renal Impairment on Pharmacokinetics of NOX-E36
Phase of Trial: Phase I
Latest Information Update: 07 May 2014
At a glance
- Drugs Emapticap pegol (Primary)
- Indications Diabetic complications; Diabetic nephropathies
- Focus Pharmacokinetics
- Sponsors NOXXON Pharma AG
- 18 Oct 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 31 Oct 2011 Additional location Moldova added as reported by ClinicalTrials.gov.
- 31 Oct 2011 Trial phase changed from I/II to I as reported by ClinicalTrials.gov.